Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

AnaptysBio, Inc. - Common Stock (NQ:ANAB)

50.76 +0.81 (+1.62%)
Streaming Delayed Price Updated: 1:39 PM EST, Feb 10, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about AnaptysBio, Inc. - Common Stock

< Previous 1 2 3 Next >
News headline image
Anaptys Announces Participation at Upcoming Investor Conferences
From AnaptysBio, Inc.
Via GlobeNewswire
News headline image
Anaptys Files Motion to Dismiss Tesaro’s Claim of Anticipatory Breach of Contract in Ongoing Litigation Against Tesaro, a GSK subsidiary
From AnaptysBio, Inc.
Via GlobeNewswire
News headline image
Anaptys to Present at the 44th Annual J.P. Morgan Healthcare Conference
From AnaptysBio, Inc.
Via GlobeNewswire
News headline image
Anaptys Announces Participation in December Investor Conferences
From AnaptysBio, Inc.
Via GlobeNewswire
News headline image
Anaptys Announces $100 Million Stock Repurchase Plan
From AnaptysBio, Inc.
Via GlobeNewswire
News headline image
Anaptys Initiates Litigation Against Tesaro, a GSK Subsidiary
From AnaptysBio, Inc.
Via GlobeNewswire
News headline image
Anaptys Announces Phase 2 Trial of Rosnilimab Did Not Meet Primary or Secondary Endpoints at Week 12 in Moderate-to-Severe Ulcerative Colitis
From AnaptysBio, Inc.
Via GlobeNewswire
News headline image
Anaptys Announces Participation in November Investor Conferences
From AnaptysBio, Inc.
Via GlobeNewswire
News headline image
Anaptys Announces Third Quarter 2025 Financial Results and Provides Business Update
From AnaptysBio, Inc.
Via GlobeNewswire
News headline image
Anaptys Announces New Positive Phase 2b Trial Results for Rosnilimab in Rheumatoid Arthritis at ACR Late-Breaking Oral Presentation
From AnaptysBio, Inc.
Via GlobeNewswire
News headline image
Anaptys Announces Late-Breaking Oral Presentation of Complete Phase 2b Data for Rosnilimab in Rheumatoid Arthritis at Upcoming ACR Convergence 2025
From AnaptysBio, Inc.
Via GlobeNewswire
News headline image
Anaptys Announces Intent to Separate Biopharma Operations from Substantial Royalty Assets by Year-end 2026
From AnaptysBio, Inc.
Via GlobeNewswire
News headline image
Anaptys to Provide Overview of ANB033, a CD122 antagonist, at Virtual Investor Event on Tuesday, Oct. 14
From AnaptysBio, Inc.
Via GlobeNewswire
News headline image
Anaptys Announces Participation in September Investor Conferences
From AnaptysBio, Inc.
Via GlobeNewswire
News headline image
Anaptys Announces Second Quarter 2025 Financial Results and Provides Business Update
From AnaptysBio, Inc.
Via GlobeNewswire
News headline image
Anaptys Announces Positive Rosnilimab Data Updated Through Six Months in Robust Phase 2b Trial in RA
From AnaptysBio, Inc.
Via GlobeNewswire
News headline image
Anaptys to Announce Updated Data from Phase 2b Trial of Rosnilimab, a PD-1 Depleter and Agonist, for Rheumatoid Arthritis on June 3, 2025
From AnaptysBio, Inc.
Via GlobeNewswire
News headline image
Anaptys Announces First Quarter 2025 Financial Results and Provides Business Update
From AnaptysBio, Inc.
Via GlobeNewswire
News headline image
Bright Peak Therapeutics Appoints John Schmid to its Board of Directors
From Bright Peak Therapeutics, Inc.
Via GlobeNewswire
News headline image
Anaptys Announces Stock Repurchase Plan
From AnaptysBio, Inc.
Via GlobeNewswire
News headline image
Anaptys Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
From AnaptysBio, Inc.
Via GlobeNewswire
News headline image
Anaptys Announces Participation in March Investor Conferences
From AnaptysBio, Inc.
Via GlobeNewswire
News headline image
Anaptys Announces Rosnilimab Achieved Positive Results in RA Phase 2b Trial and Highest Ever Reported CDAI LDA Response Over 6 Months
From AnaptysBio, Inc.
Via GlobeNewswire
News headline image
Anaptys to Announce Top-line Data from Phase 2b Trial of Rosnilimab, a PD-1 Depleter and Agonist, in Rheumatoid Arthritis on Feb. 12, 2025
From AnaptysBio, Inc.
Via GlobeNewswire
News headline image
Anaptys to Present at the Guggenheim SMID Cap Biotech Conference
From AnaptysBio, Inc.
Via GlobeNewswire
News headline image
Vanda Pharmaceuticals and Anaptys Announce Exclusive Global License Agreement for Vanda to Develop and Commercialize Imsidolimab, an IL-36R Antagonist
From AnaptysBio, Inc.
Via GlobeNewswire
News headline image
Anaptys to Present at the 43rd Annual J.P. Morgan Healthcare Conference
From AnaptysBio, Inc.
Via GlobeNewswire
News headline image
Anaptys Announces Phase 2b Trial of ANB032, a BTLA Agonist, Did Not Meet Primary or Secondary Endpoints in Atopic Dermatitis
From AnaptysBio, Inc.
Via GlobeNewswire
News headline image
Anaptys Announces Participation in November and December Investor Conferences
From AnaptysBio, Inc.
Via GlobeNewswire
News headline image
Anaptys Announces Third Quarter 2024 Financial Results and Provides Business Update
From AnaptysBio, Inc.
Via GlobeNewswire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.